bf/NASDAQ:SAGE_icon.jpeg

NASDAQ:SAGE

Sage Therapeutics

  • Stock

7.48

+2.61%

−1.20

USD last updated 14/08 01:46:41

Last Close

8.68

30/07 22:20

Market Cap

663.81M

Beta: 1.15

Volume Today

1.30M

Avg: 531.49K

PE Ratio

−2.29

PFCF: −2.65

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III c...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -4-3-2-12017-05-092019-05-022021-05-042023-05-022024-10-29

    Revenue (Estimate*)

    200M400M600M800M1B1.20B2017-05-092019-05-022021-05-042023-05-022024-10-29

    *Estimate based on analyst consensus